Yunhee Choi

Yunhee Choi

Auto-generated profile, based on publicly available information

Yunhee Choi

Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Radiology
Verified
Journal Article
Closed access
BKBo Ra Kwon
Bo Ra Kwon
SSSung Ui Shin
Sung Ui Shin
SKSoo-Yeon Kim
Soo-Yeon Kim
YCYunhee Choi
Yunhee Choi
NCNariya Cho
Nariya Cho
WMWoo Kyung Moon
Woo Kyung Moon
Microcalcifications on mammograms obtained before neoadjuvant chemotherapy (NAC), peritumoral edema on MRI scans obtained after NAC, and clinical-pathologic variables were associated with survival ... Background Little is known regarding findings at imaging associated with survival in patients with luminal breast cancer treated with neoadjuvant chemotherapy (NAC). Purpose To determine the relati...

1 May 2024 in Radiology
Verified
Journal Article
Closed access
KKKoung Mi Kang
Koung Mi Kang
JSJiyoung Song
Jiyoung Song
YCYunhee Choi
Yunhee Choi
CPChanrim Park
Chanrim Park
JPJi Eun Park
Ji Eun Park
SCSeung Hong Choi
Seung Hong Choi
Simple scoring systems using standard clinical MRI were developed and validated for predicting isocitrate dehydrogenase and 1p/19q codeletion status in adult-type diffuse gliomas lacking contrast enhancement.

1 September 2024 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
JLJong Hyuk Lee
Jong Hyuk Lee
Dongheon LeeDongheon Lee
Dongheon Lee
MLMichael T. Lu
Michael T. Lu
VRVineet K. Raghu
Vineet K. Raghu
JGJin Mo Goo
Jin Mo Goo
HKHyungjin Kim
Hyungjin Kim
"Just Accepted" papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content. Purpose To assess the prognostic value of a deep learning-based chest radiographic age (CXR-Age) model in a large external test cohort of Asian individuals. Materials and Methods This single-center, retrospective study included chest radiographs from consecutive, asymptomatic Asian individuals aged 50 to 80 who received health check-ups between January 2004 and June 2018. This study performed a dedicated external test of the previously developed CXR-Age model, which predicts an age adjusted based on the risk of all-cause mortality. Adjusted hazard ratios (HRs) of CXR-Age for all-cause, cardiovascular, lung cancer, and respiratory disease mortality were assessed using multivariable Cox or Fine-Gray models, with their added values evaluated by likelihood ratio tests. Results A total of 36,924 individuals (mean chronological age ± SD, 58 ± 7 years; CXR-Age, 60 ± 5 years; 22,352 male) were included. Over a median follow-up of 11.0 years, 1250 individuals (3.4%) died, including 153 cardiovascular (0.4%), 166 lung cancer (0.4%), and 98 respiratory deaths (0.3%). CXR-Age was a significant risk factor for all-cause (adjusted HR at the chronological age of 50 years: 1.03; at 60 years: 1.05; at 70 years: 1.07), cardiovascular (adjusted HR: 1.11), lung cancer (adjusted HR for former smokers: 1.12; for current smokers: 1.05), and respiratory disease mortality (adjusted HR: 1.12) (all P values < 0.05). The likelihood ratio test demonstrated added prognostic value of CXR-Age to clinical factors including chronological age for all outcomes (all P values < 0.001). Conclusion Deep learning-based chest radiographic age was associated with various survival outcomes and had added value to clinical factors in asymptomatic Asian individuals, suggesting its generalizability. ©RSNA, 2024.

30 September 2024 in Neurospine
Verified
Journal Article
Open access
PDF file
HPHangeul Park
Hangeul Park
YCYunhee Choi
Yunhee Choi
SLSungjoon Lee
Sungjoon Lee
SLSun-Ho Lee
Sun-Ho Lee
EKEun-Sang Kim
Eun-Sang Kim
CCChun Kee Chung
Chun Kee Chung
Objective: Chordoma, a rare malignant tumor originating from embryonal notochord remnants, exhibits high resistance to conventional treatments, making surgical resection imperative. However, the factors influencing prognosis specifically for cervical spine chordoma have not been clearly identified. We investigate the prognosis of cervical spine chordoma with factors influential in a nationwide multicenter retrospective study.Methods: This study included all patients diagnosed with cervical spine chordoma at 7 tertiary referral centers from January 1998 to March 2023, excluding those with clivus and thoracic spine chordomas extending into the cervical spine. Local recurrence (LR) was identified through follow-up magnetic resonance imaging, either as reappearance in completely resected tumors or regrowth in residual tumors. The study assessed LR and overall survival, analyzing factors influencing LR and death.Results: Forty-five patients with cervical spine chordoma had a mean age of 46.4 years. Over a median follow-up of 52 months, LR and distant metastasis were observed in 21 (46.7%) and 4 patients (8.9%), respectively, and 16 patients (36%) were confirmed dead. The 5-year and 10-year cumulative LR rates were 51.3% and 60%, respectively, while the 5-year and 10-year survival rates were 82% and 53%. Age was the only significant factor affecting mortality (hazard ratio, 1.04; 95% confidence interval, 1.04–1.07; p=0.015). Notably, the degree of resection and adjuvant therapy did not statistically significantly impact local tumor control and mortality.Conclusion: This study, the largest multicenter retrospective analysis of cervical spine chordoma in Korea, identified age as the only factor significantly affecting patient survival.

1 October 2025 in Radiology
Verified
Journal Article
Closed access
HYHeera Yoen
Heera Yoen
HSHee-Chul Shin
Hee-Chul Shin
KYKyung-Hwak Yoon
Kyung-Hwak Yoon
JOJeong Hun Oh
Jeong Hun Oh
JPJiwon Park
Jiwon Park
HKHong-Kyu Kim
Hong-Kyu Kim
Undergoing preoperative MRI was associated with reduced risk of ipsilateral in-breast recurrence in patients 50 years or younger with breast cancer, with the greatest benefit observed in those with hormone receptor–negative cancers.

4 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JKJoong-Yub Kim
Joong-Yub Kim
HHHyeontaek Hwang
Hyeontaek Hwang
DYDaHae Yim
DaHae Yim
YCYunhee Choi
Yunhee Choi
TKTaek Soo Kim
Taek Soo Kim
JYJae-Joon Yim
Jae-Joon Yim
Mycobacterium avium complex pulmonary disease (MAC-PD) is a chronic lung condition with rapidly increasing prevalence worldwide. Macrolides like azithromycin and clarithromycin are the backbone of long-term antibiotic therapy for progressive MAC-PD. The impact of minimum inhibitory concentrations (MICs), especially within the susceptible range, for macrolides on treatment responses remains unclear. We analyzed adult patients who started treatment for MAC-PD between 1 March 2009 and 1 March 2022 at Seoul National University Hospital. Patients were categorized into four groups according to the clarithromycin MICs of their causative strains at treatment initiation. Logistic regression was employed to evaluate the impact of clarithromycin MICs on the microbiological cure rate. Companion drugs and their MICs, alongside clinical characteristics like age, sex, body mass index, cavity presence, acid-fast bacilli smear positivity, causative species, and erythrocyte sedimentation rate were adjusted in multivariable analysis. Four-hundred thirty-six patients (median age, 65 years; 34% men) were included. Microbiological cure rates were 51.8%, 51.9%, 50.0%, and 18.2% for patients with clarithromycin MICs ≤0.5, 1–2, 4–8, and ≥32 µg/mL, respectively (P=0.181). No significant differences in microbiological cure rates were observed across varying levels of clarithromycin MICs within the susceptible range (≤8 µg/mL). Relative to patients with clarithromycin-susceptible strains, patients with MICs ≥32 µg/mL had an odds ratio of 0.25 for achieving microbiological cure (95% confidence interval, 0.06–1.07; P=0.06). Treatment responses were comparable among patients with strains having clarithromycin MICs within the susceptible range, but were likely to be worse for patients with strains having MICs ≥32 µg/mL.